Dynavax Technologies Corporation (DVAX)
Market Cap | 1.45B |
Revenue (ttm) | 236.15M |
Net Income (ttm) | 9.22M |
Shares Out | 130.89M |
EPS (ttm) | 0.06 |
PE Ratio | 184.67 |
Forward PE | 42.73 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,002,888 |
Open | 11.17 |
Previous Close | 11.16 |
Day's Range | 11.05 - 11.35 |
52-Week Range | 10.48 - 15.15 |
Beta | 1.19 |
Analysts | Buy |
Price Target | 25.33 (+128.61%) |
Earnings Date | Aug 1, 2024 |
About DVAX
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, In... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $25.33, which is an increase of 128.61% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/8/i/press19-2500779.jpg)
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
![](https://cdn.snapi.dev/images/v1/y/g/conf10-2450595.jpg)
Dynavax to Present at Upcoming Investor Conferences
EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...
![](https://cdn.snapi.dev/images/v1/u/c/biotech26-2429378.jpg)
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies' hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday.
![](https://cdn.snapi.dev/images/v1/5/z/press14-2429303.jpg)
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
EMERYVILLE, Calif. , May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA)...
![](https://cdn.snapi.dev/images/v1/s/r/press13-2419202.jpg)
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
HEPLISAV-B ® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - ...
![](https://cdn.snapi.dev/images/v1/n/v/conf8-2389409.jpg)
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
EMERYVILLE, Calif. , April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wi...
![](https://cdn.snapi.dev/images/v1/j/5/conf20-2297414.jpg)
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
EMERYVILLE, Calif. , Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
![](https://cdn.snapi.dev/images/v1/1/p/press17-2289703.jpg)
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
HEPLISAV-B ® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expecte...
![](https://cdn.snapi.dev/images/v1/r/h/conf20-2268288.jpg)
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
EMERYVILLE, Calif. , Feb. 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will...
![](https://cdn.snapi.dev/images/v1/q/o/press3-2220348.jpg)
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
Preliminary full year 2023 HEPLISAV-B ® vaccine net product revenue of approximately $213 million, a 69% year-over-year increase Significant gains in HEPLISAV-B market share in key market segments, wi...
![](https://cdn.snapi.dev/images/v1/r/t/conf11-2215654.jpg)
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif. , Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...
![](https://cdn.snapi.dev/images/v1/a/6/im-09753645size1777777777777778width800-2208256.jpg)
20 favorite small-cap stocks for 2024 among Wall Street analysts
The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...
![](https://cdn.snapi.dev/images/v1/c/k/conf10-2166211.jpg)
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
![](https://cdn.snapi.dev/images/v1/e/0/press16-2137565.jpg)
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
Generated quarterly HEPLISAV-B ® vaccine net product revenue of $62.3 million, a 66% year-over-year increase Raising full year HEPLISAV-B net product revenue guidance to $210 - $220 million, compared ...
![](https://cdn.snapi.dev/images/v1/d/k/conf13-2124291.jpg)
Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
EMERYVILLE, Calif. , Oct. 26, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil...
![](https://cdn.snapi.dev/images/v1/9/j/conf20-2111919.jpg)
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
EMERYVILLE, Calif., Oct. 19, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...
![](https://cdn.snapi.dev/images/v1/q/m/conf9-2052450.jpg)
Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
EMERYVILLE, Calif. , Sept. 6, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
![](https://cdn.snapi.dev/images/v1/w/j/press10-2005800.jpg)
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
Generated record quarterly HEPLISAV-B ® vaccine net product revenue of $56 million, a 73% year-over-year increase Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compa...
![](https://cdn.snapi.dev/images/v1/g/2/conf3-1981418.jpg)
Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
EMERYVILLE, Calif. , July 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil...
![](https://cdn.snapi.dev/images/v1/t/o/conf20-1877967.jpg)
Dynavax to Present at the JMP Securities Life Sciences Conference
EMERYVILLE, Calif. , May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today...
![](https://cdn.snapi.dev/images/v1/t/t/press17-1866809.jpg)
Dynavax Reports First Quarter 2023 Financial Results
HEPLISAV-B ® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023 Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $...
![](https://cdn.snapi.dev/images/v1/t/q/conf19-1842531.jpg)
Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023
EMERYVILLE, Calif. , April 18, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wi...
![](https://cdn.snapi.dev/images/v1/q/3/press15-1778618.jpg)
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
Saint - Herblain ( France), March 2 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an updat...
![](https://cdn.snapi.dev/images/v1/u/k/conf10-1778148.jpg)
Dynavax to Present at the Cowen 43rd Annual Health Care Conference
EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
![](https://cdn.snapi.dev/images/v1/x/e/press20-1774134.jpg)
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine
HEPLISAV B is the only two-dose adult hepatitis B vaccine offering protection in just one month EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a bi...